Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Advanced Lung Cancer

Pfizer

Status and phase: Completed; Phase 1

Conditions: Carcinoma, Non-Small-Cell Lung

Treatments: Drug: CP-751,871 + carboplatin + paclitaxel

Study type: Interventional

Funder types: Industry

Identifiers

NCT00603538

A4021019

Japan CTPN 19-2409

Details and patient eligibility

About

Investigate safety, tolerability and pharmacokinetics of CP-751,871 when given in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer

Enrollment: 19 patients

Sex: All

Ages: 20 to 74 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of advanced non-small cell lung cancer
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion criteria

• Any prior treatment for non-small cell lung cancer
• Brain metastases
• With diabetes

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

19 participants in 1 patient group

CP-751,871

Experimental group

Treatment:

Drug: CP-751,871 + carboplatin + paclitaxel